CJC-1295
A synthetic GHRH (growth hormone-releasing hormone) analog that stimulates the pituitary to release endogenous growth hormone. The DAC variant has an extended half-life of ~8 days, creating sustained GH elevation.
Mechanism of Action
Mimics endogenous GHRH by binding to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating natural GH secretion. The Drug Affinity Complex (DAC) modification allows albumin binding, extending half-life dramatically. Increases both GH pulse amplitude and frequency. Downstream effects mediated through GH → IGF-1 axis.
Typical Dosing
⚠ Warning Flags
- •Water retention is common
- •Mild insulin resistance at higher doses
- •Headaches and flushing reported
- •Best used synergistically with a GHRP (e.g., Ipamorelin)
Effect Profile
Side Effect Profile
Research Studies
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. · 2006
CJC-1295 DAC produced sustained 2-10x increases in GH and 1.5-3x increases in IGF-1 after single administration.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout (GHRHKO) mouse
Alba M et al. · 2006
Confirmed CJC-1295 restores normal GH secretion patterns in GHRH-deficient models.
Novel growth hormone secretagogues: clinical perspectives and therapeutic potential
Ionescu M, Bhatt DL · 2004
Reviews GH secretagogue pharmacokinetics and their endocrine effects on the somatotropic axis.